Table 2.
Characteristics | 1st round screening | 2nd round screening | Total | |||
---|---|---|---|---|---|---|
No. of cases | Interval cases (N, %) | No. of cases | Interval cases (N, %) | No. of cases | Interval cases (N, %) | |
Overall | 51 | 11 (21.6) | 13 | 2 (15.4) | 64 | 13 (20.3) |
Age group | ||||||
40- | 6 | 0 | 3 | 0 | 9 | 0 |
50- | 25 | 7 (28.0) | 3 | 1 (33.3) | 28 | 8 (28.6) |
60- | 16 | 3 (18.8) | 6 | 1 (16.7) | 22 | 4 (18.2) |
70- | 4 | 1 (25.0) | 1 | 0 | 5 | 1 (20.0) |
Pathological type | ||||||
DCIS | 8 | 2 (25.0) | 0 | 0 | 8 | 2 (25.0) |
DCIS with micro-invasive | 5 | 1 (20.0) | 2 | 0 | 7 | 1 (14.3) |
IDC | 34 | 6 (17.7) | 9 | 1 (11.1) | 43 | 7 (16.3) |
Special types | 3 | 2 (66.7) | 2 | 1 (50.0) | 5 | 3 (60.0) |
Size (mm) | ||||||
DCIS | 13 | 3 (23.1) | 3 | 0 | 16 | 3 (18.8) |
< 20 | 12 | 3 (25.0) | 5 | 2 (40.0) | 17 | 5 (29.4) |
20- | 23 | 4 (17.4) | 4 | 0 | 27 | 4 (14.8) |
50- | 2 | 1 (50.0) | 0 | 0 | 2 | 1 (50.0) |
Axillary lymph node status | ||||||
Negative | 40 | 10 (25.0) | 12 | 2 (16.7) | 52 | 12 (23.1) |
Positive | 10 | 1 (10.0) | 0 | 0 | 10 | 1 (10.0) |
Stage | ||||||
DCIS a | 13 | 3 (23.1) | 3 | 0 | 16 | 3 (18.8) |
I | 15 | 3 (20.0) | 8 | 2 (25.0) | 23 | 5 (21.7) |
IIA | 14 | 3 (21.4) | 1 | 0 | 15 | 3 (20.0) |
IIB | 6 | 1 (16.7) | 0 | 0 | 6 | 1 (16.7) |
III-IV | 2 | 1 (50.0) | 0 | 0 | 2 | 1 (50.0) |
ER status | ||||||
Positive | 35 | 7 (20.0) | 9 | 2 (22.2) | 44 | 9 (20.5) |
Negative | 13 | 4 (30.8) | 3 | 0 | 16 | 4 (25.0) |
PgR status | ||||||
Positive | 30 | 4 (13.3) | 9 | 2 (22.2) | 39 | 6 (15.4) |
Negative | 18 | 7 (38.9) | 3 | 0 | 21 | 7 (33.3) |
a both DCIS and DCIS with micro-invasive;
Missing values were excluded from the analysis (1 for pathological type, 2 for tumor size, axillary lymph node status and stage, 4 for ER and PgR status).
Abbreviations: DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ER estrogen receptor, PgR progesterone receptor.